A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults with Non-Small Cell Lung Cancer in Combination with Pembrolizumab.

Condition studied

Non Small Cell Lung Cancer

Investigational medicinal product(s)

Eligibility

Primary endpoint

ORR per Investigator assessment using RECIST 1.1

Endpoint detail

DoR per Investigator assessment using RECIST 1.1 • DCR per Investigator assessment using RECIST 1.1 • CBR per Investigator assessment using RECIST 1.1 • PFS per Investigator assessment using RECIST 1.1 • OS, • AEs • Clinical laboratory data, Integrated analysis using population PK model approach, Please refer to Protocol for further secondary end points